Description
Composition- Sitagliptin 100 mg + Dapagliflozin 10 mg
Mode of Action- Combines incretin enhancement and urinary glucose excretion to improve blood glucose control with low hypoglycemia risk.
USPs- Dual oral diabetes support; weight-neutral/weight benefit potential; effective modern combination therapy.
Prescribing Specialties- Diabetologist, General Physician
